131 related articles for article (PubMed ID: 27448776)
1. Identification of the first small-molecule inhibitor of the REV7 DNA repair protein interaction.
Actis ML; Ambaye ND; Evison BJ; Shao Y; Vanarotti M; Inoue A; McDonald ET; Kikuchi S; Heath R; Hara K; Hashimoto H; Fujii N
Bioorg Med Chem; 2016 Sep; 24(18):4339-4346. PubMed ID: 27448776
[TBL] [Abstract][Full Text] [Related]
2. REV7 is essential for DNA damage tolerance via two REV3L binding sites in mammalian DNA polymerase ζ.
Tomida J; Takata K; Lange SS; Schibler AC; Yousefzadeh MJ; Bhetawal S; Dent SY; Wood RD
Nucleic Acids Res; 2015 Jan; 43(2):1000-11. PubMed ID: 25567983
[TBL] [Abstract][Full Text] [Related]
3. Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer.
Vassel FM; Bian K; Walker GC; Hemann MT
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28922-28924. PubMed ID: 33144509
[TBL] [Abstract][Full Text] [Related]
4. A small molecule inhibitor of monoubiquitinated Proliferating Cell Nuclear Antigen (PCNA) inhibits repair of interstrand DNA cross-link, enhances DNA double strand break, and sensitizes cancer cells to cisplatin.
Inoue A; Kikuchi S; Hishiki A; Shao Y; Heath R; Evison BJ; Actis M; Canman CE; Hashimoto H; Fujii N
J Biol Chem; 2014 Mar; 289(10):7109-7120. PubMed ID: 24474685
[TBL] [Abstract][Full Text] [Related]
5. REV3L modulates cisplatin sensitivity of non-small cell lung cancer H1299 cells.
Wang W; Sheng W; Yu C; Cao J; Zhou J; Wu J; Zhang H; Zhang S
Oncol Rep; 2015 Sep; 34(3):1460-8. PubMed ID: 26165320
[TBL] [Abstract][Full Text] [Related]
6. Rev7, the regulatory subunit of Polζ, undergoes UV-induced and Cul4-dependent degradation.
Bhat A; Qin Z; Wang G; Chen W; Xiao W
FEBS J; 2017 Jun; 284(12):1790-1803. PubMed ID: 28440919
[TBL] [Abstract][Full Text] [Related]
7. [Structural Basis of the Multifunctional Hub Protein and Identification of a Small-molecule Compound for Drug Discovery].
Hara K
Yakugaku Zasshi; 2019; 139(7):969-973. PubMed ID: 31257254
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
[TBL] [Abstract][Full Text] [Related]
9. REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells.
Yang L; Shi T; Liu F; Ren C; Wang Z; Li Y; Tu X; Yang G; Cheng X
PLoS One; 2015; 10(3):e0120334. PubMed ID: 25781640
[TBL] [Abstract][Full Text] [Related]
10. Backbone and ILV side-chain methyl NMR resonance assignments of human Rev7/Rev3-RBM1 and Rev7/Rev3-RBM2 complexes.
Arianna GA; Geddes-Buehre DH; Korzhnev DM
Biomol NMR Assign; 2023 Jun; 17(1):107-114. PubMed ID: 37129702
[TBL] [Abstract][Full Text] [Related]
11. A novel assay revealed that ribonucleotide reductase is functionally important for interstrand DNA crosslink repair.
Fujii N; Evison BJ; Actis ML; Inoue A
Bioorg Med Chem; 2015 Nov; 23(21):6912-21. PubMed ID: 26462050
[TBL] [Abstract][Full Text] [Related]
12. A missense mutation in Rev7 disrupts formation of Polζ, impairing mouse development and repair of genotoxic agent-induced DNA lesions.
Khalaj M; Abbasi A; Yamanishi H; Akiyama K; Wakitani S; Kikuchi S; Hirose M; Yuzuriha M; Magari M; Degheidy HA; Abe K; Ogura A; Hashimoto H; Kunieda T
J Biol Chem; 2014 Feb; 289(6):3811-24. PubMed ID: 24356953
[TBL] [Abstract][Full Text] [Related]
13. Structural basis for shieldin complex subunit 3-mediated recruitment of the checkpoint protein REV7 during DNA double-strand break repair.
Dai Y; Zhang F; Wang L; Shan S; Gong Z; Zhou Z
J Biol Chem; 2020 Jan; 295(1):250-262. PubMed ID: 31796627
[TBL] [Abstract][Full Text] [Related]
14. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy.
Wojtaszek JL; Chatterjee N; Najeeb J; Ramos A; Lee M; Bian K; Xue JY; Fenton BA; Park H; Li D; Hemann MT; Hong J; Walker GC; Zhou P
Cell; 2019 Jun; 178(1):152-159.e11. PubMed ID: 31178121
[TBL] [Abstract][Full Text] [Related]
15. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
Gentile F; Tuszynski JA; Barakat KH
J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
[TBL] [Abstract][Full Text] [Related]
16. Small molecule inhibitors of PCNA/PIP-box interaction suppress translesion DNA synthesis.
Actis M; Inoue A; Evison B; Perry S; Punchihewa C; Fujii N
Bioorg Med Chem; 2013 Apr; 21(7):1972-7. PubMed ID: 23395113
[TBL] [Abstract][Full Text] [Related]
17. Involvement of translesion synthesis DNA polymerases in DNA interstrand crosslink repair.
Roy U; Schärer OD
DNA Repair (Amst); 2016 Aug; 44():33-41. PubMed ID: 27311543
[TBL] [Abstract][Full Text] [Related]
18. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.
Xu ZY; Loignon M; Han FY; Panasci L; Aloyz R
J Pharmacol Exp Ther; 2005 Aug; 314(2):495-505. PubMed ID: 15843498
[TBL] [Abstract][Full Text] [Related]
19. A facile synthesis and biological activity of novel tetrahydrobenzo[4',5']thieno[3',2':5,6]pyrido[4,3-d]pyrimidin-4(3H)-ones.
Ren Q; Liang YJ; He H; Fu L; Gu Y
Bioorg Med Chem Lett; 2009 Dec; 19(23):6713-6. PubMed ID: 19846302
[TBL] [Abstract][Full Text] [Related]
20. Overlapping in short motif sequences for binding to human REV7 and MAD2 proteins.
Hanafusa T; Habu T; Tomida J; Ohashi E; Murakumo Y; Ohmori H
Genes Cells; 2010 Mar; 15(3):281-96. PubMed ID: 20088965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
